By Diane Tezeno
Empower Magazine is excited to introduce a new column called “Empowering Firsts” that will spotlight individuals who have achieved a significant first in their industry or field of pursuit. With the debut of this column, we celebrate the achievements of Darnisha Grant Harrison, one of the first African American females to serve as founder, president and CEO of a pharmaceutical company in the U.S.
Harrison’s early childhood dreams were to attend the Julliard School of Music to pursue a career in acting. In her senior year in high school, her dreams changed after attending a summer preceptorship at Louisiana State University School of Veterinary Medicine that allowed her to utilize her math and science skills to do scientific research in public health. The experience led her to major in a scientific discipline at Louisiana State University, changing the course of her life.
Name: Darnisha Grant Harrison, 42
Birthplace: Baton Rouge, La.
Education: Bachelor of science degree in microbiology, minor in chemistry from Louisiana State University and Agricultural and Mechanical College
Company: Founder/President/CEO of Ennaid Therapeutics
First Job: University of Georgia, 1994-1996, in conjunction with the veterinary school working under a university grant to develop a vaccine against a particular strain of E-coli bacteria.
Entry into Pharmaceutical Industry: Worked at Amgen, one of the world’s leading pharmaceutical companies, based in California.
Pharmaceutical Experience: 13 years experience in business development in the pharmaceutical R&D sector of the pharmaceutical industry as a director of business development within many notable companies across the globe, including Metrics, Inc.”
Business Launch: September 2012
Company Overview: Ennaid Therapeutics, Inc. is a development stage, global biopharmaceutical company focused on the development and commercialization of vaccines for infectious diseases. Ennaid’s lead compound is a first-in-class platform technology that prevents some of the world’s most harmful and deadly viruses: Dengue virus, West Nile Virus and Hepatitis C virus. Using this technology, we are developing a Dengue virus vaccine that targets all four serotypes of Dengue virus.
Company Logo: Translating Complex Science Into Today’s Cures.
Company’s Mission: Birthed out of a desire to bring cures and prevention to incurable and rare diseases by translating complex science into medicines while employing a strategic, accelerated platform to develop and commercialize such therapies. We do not wish to merely treat disease symptoms, as we have an explicit vision to dispel the impossible by developing and commercializing medicines for incurable and rare diseases. We have uniquely positioned our company to be a key player in the biotechnology/pharmaceutical space, and are dedicated to improving the health and saving lives of patients across the globe.
Goal in Five Years: On the way to being the No. 1 pharmaceutical company in the world and aggressively focusing on finding first-in-class therapies in cancer, autoimmune disorders and diseases of the eye.
Offices: In Atlanta, Georgia and Baton Rouge, Louisiana
Investor Inquiries: As a new venture, Ennaid is currently raising start-up capital to advance ETX-101 as we continue to build a rich development pipeline around West Nile Virus and Hepatitis C Virus in the future. For more information and to discuss available investment or licensing opportunities in the high growth pharmaceutical marketplace, contact a company representative via email at email@example.com or call 225-954-1599.
Darnisha Grant Harrison | P.O. Box 84172 Baton Rouge, La. 70884 | Office phone -225-954-1599 | Fax – 866-787-4314 | Website: www.ennaidthera.com.